Business
Unaudited Interim Report
Unaudited Interim Report.
About this update from Nuformix Plc
[{"type":"text","content":"\n\nNuformix plc\n \n(\"Nuformix\", the \"Company\" or the \"Group\")\n \nUnaudited Interim Report\n \n22 May 2023: Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its unaudited results for the twelve months ended 31 March 2023 following the change in the Company's accounting reference date from 31 March to 30 September.\n \nOperational highlights\n \n· The Company successfully conducted studies in state-of-the-art 3D human Idiopathic Pulmonary Fibrosis (\"IPF\") lung tissue, using a disease and species relevant model, which initially focused on the anti-fibrotic action of NXP002 in combination with current standards-of-care (\"SoC\"). The results indicated:\no NXP002 alone delivered a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis; and\no Both high and low concentrations of NXP002 showed an additive anti-fibrotic effect to SoC.\n \n· The anti-inflammatory action of NXP002 was subsequently investigated, post period end, in the same model and the results indicated:\no NXP002 alone delivered a strong, consistent anti-inflammatory effect as demonstrated by modulation of the release of multiple biomarkers of inflammation; and\no NXP002 increased the performance of SoCs in modulating the release of a panel of inflammation biomarkers associated with the progression of fibrotic lung disease.\n \n· The Company additionally successfully conducted duration of action studies using an exploratory 3D human lung tissue model offering species relevance and NXP002 dosage control. This allowed investigation of NXP002's anti-inflammatory action at various timepoints following challenge with lipopolysaccharide (\"LPS\"), a stimulant that induces measurable endpoints and pathways relevant to IPF progression. The results indicated:\no NXP002 suppresses the release of inflammatory cytokines by healthy human lung tissue following LPS challenge; and\no A strong anti-inflammatory effect remains at 12 hours post drug dosing demonstrated by continued suppression of the release of inflammatory cytokines following LPS challenge, confirming NXP002 has a suitable du...